{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:06:16Z","timestamp":1782950776514,"version":"3.54.5"},"reference-count":64,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004565","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2022R1I1A1A01053839"],"award-info":[{"award-number":["2022R1I1A1A01053839"]}],"id":[{"id":"10.13039\/501100004565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004565","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1A6A1A03038890"],"award-info":[{"award-number":["2021R1A6A1A03038890"]}],"id":[{"id":"10.13039\/501100004565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteomorphs are a newly described osteoclast lineage cell in mice, which are suggested to play a significant role in the maintenance of bone resorption. Preclinical investigations revealed that osteomorphs are generated through the fission of multinucleated bone-resorbing osteoclasts and can also re-fuse with existing osteoclasts. Modifications to RANKL signaling have been shown to alter cycles of fission and re-fusion of osteomorphs in mice. These novel findings were also shown to contribute to the rebound phenomenon after cessation of anti-RANKL therapy in mice. Moreover, the absence of osteomorph-specific genes in mice exhibits bone structural and quality phenotypes. Given these insights, it could be speculated that osteomorphs play a significant role in bone homeostasis, bone metabolic diseases, and response to therapeutics. In this review, we discuss these potential translational roles for osteomorphs. Importantly, we highlight the need for future preclinical and clinical studies to verify the presence of osteomorphs in humans and explore further the translational implications of this discovery.<\/jats:p>","DOI":"10.1210\/clinem\/dgad711","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T22:41:55Z","timestamp":1701988915000},"page":"e1373-e1378","source":"Crossref","is-referenced-by-count":6,"title":["New Horizons: Translational Aspects of Osteomorphs"],"prefix":"10.1210","volume":"109","author":[{"given":"Kyung-Hyun","family":"Park-Min","sequence":"first","affiliation":[{"name":"Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery , New York, NY 10021 , USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY 10065 , USA"},{"name":"BCMB Allied Program, Weill Cornell Graduate School of Medical Sciences , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hwan","family":"Mun","sequence":"additional","affiliation":[{"name":"Research Institute of Women\u2019s Health, Sookmyung Women's University , 140-742 Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bockman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY 10065 , USA"},{"name":"Endocrine Service, Hospital for Special Surgery , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-2506","authenticated-orcid":false,"given":"Michelle M","family":"McDonald","sequence":"additional","affiliation":[{"name":"Skeletal Diseases Program, Garvan Institute of Medical Research , Darlinghurst, NSW 2010 , Australia"},{"name":"School of Medical Science, Faculty of Medicine and Health, The University of Sydney , Sydney, NSW 2006 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"issue":"4","key":"2024041923080914200_dgad711-B1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024041923080914200_dgad711-B2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bone.2013.10.024","article-title":"Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients","volume":"59","author":"Jobke","year":"2014","journal-title":"Bone"},{"issue":"12","key":"2024041923080914200_dgad711-B3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2024041923080914200_dgad711-B4","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"issue":"10","key":"2024041923080914200_dgad711-B5","first-page":"801","article-title":"Catabolic and anabolic actions of parathyroid hormone on the skeleton","volume":"34","author":"Silva","year":"2011","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2024041923080914200_dgad711-B6","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","article-title":"Catabolic effects of continuous human PTH (1\u201338) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation","volume":"142","author":"Ma","year":"2001","journal-title":"Endocrinology"},{"issue":"11","key":"2024041923080914200_dgad711-B7","doi-asserted-by":"crossref","first-page":"e0142519","DOI":"10.1371\/journal.pone.0142519","article-title":"Osteoprotegerin induces apoptosis of osteoclasts and osteoclast precursor cells via the fas\/fas ligand pathway","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"2024041923080914200_dgad711-B8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators\u2014mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med"},{"issue":"7753","key":"2024041923080914200_dgad711-B9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41586-019-1105-7","article-title":"Developmental origin, functional maintenance and genetic rescue of osteoclasts","volume":"568","author":"Jacome-Galarza","year":"2019","journal-title":"Nature"},{"issue":"2","key":"2024041923080914200_dgad711-B10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.11005\/jbm.2023.30.2.127","article-title":"Origin of osteoclasts: osteoclast precursor cells","volume":"30","author":"Tsai","year":"2023","journal-title":"J Bone Metab"},{"issue":"5","key":"2024041923080914200_dgad711-B11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"issue":"1","key":"2024041923080914200_dgad711-B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41232-022-00213-x","article-title":"Osteoclast biology in the single-cell era","volume":"42","author":"Tsukasaki","year":"2022","journal-title":"Inflamm Regen"},{"issue":"5","key":"2024041923080914200_dgad711-B13","doi-asserted-by":"crossref","first-page":"106682","DOI":"10.1016\/j.isci.2023.106682","article-title":"Effect of mitophagy in the formation of osteomorphs derived from osteoclasts","volume":"26","author":"Huang","year":"2023","journal-title":"iScience"},{"issue":"4","key":"2024041923080914200_dgad711-B14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ajco.12517","article-title":"Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures","volume":"13","author":"Pittman","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"2024041923080914200_dgad711-B15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024041923080914200_dgad711-B16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024041923080914200_dgad711-B17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2024041923080914200_dgad711-B18","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: fREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2024041923080914200_dgad711-B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2024041923080914200_dgad711-B20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","article-title":"Denosumab discontinuation","volume":"21","author":"Solling","year":"2023","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"2024041923080914200_dgad711-B21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00198-022-06651-0","article-title":"Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption","volume":"34","author":"Solling","year":"2023","journal-title":"Osteoporos Int"},{"issue":"18","key":"2024041923080914200_dgad711-B22","doi-asserted-by":"crossref","first-page":"e167790","DOI":"10.1172\/jci.insight.167790","article-title":"Reduced OPG expression by osteocytes may contribute to rebound resorption after denosumab discontinuation","volume":"8","author":"Fu","year":"2023","journal-title":"JCI Insight"},{"issue":"9","key":"2024041923080914200_dgad711-B23","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00198-020-05785-3","article-title":"Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis","volume":"32","author":"Saag","year":"2021","journal-title":"Osteoporos Int"},{"issue":"24","key":"2024041923080914200_dgad711-B24","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"2024041923080914200_dgad711-B25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Fracture Intervention Trial Long-Term Extension Research G. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024041923080914200_dgad711-B26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"key":"2024041923080914200_dgad711-B27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone"},{"issue":"13","key":"2024041923080914200_dgad711-B28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"issue":"13","key":"2024041923080914200_dgad711-B29","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMe038143","article-title":"Parathyroid hormone plus alendronate\u2013a combination that does not add up","volume":"349","author":"Khosla","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"2024041923080914200_dgad711-B30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2016.01.004","article-title":"Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (denosumab and teriparatide administration) study randomized controlled trial","volume":"19","author":"Leder","year":"2016","journal-title":"J Clin Densitom"},{"issue":"5","key":"2024041923080914200_dgad711-B31","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024041923080914200_dgad711-B32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024041923080914200_dgad711-B33","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study","volume":"27","author":"Langdahl","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024041923080914200_dgad711-B34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jor.22982","article-title":"Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model","volume":"34","author":"Pennypacker","year":"2016","journal-title":"J Orthop Res"},{"issue":"4","key":"2024041923080914200_dgad711-B35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1210\/er.2015-1114","article-title":"Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned","volume":"38","author":"Drake","year":"2017","journal-title":"Endocr Rev"},{"issue":"11","key":"2024041923080914200_dgad711-B36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"2024041923080914200_dgad711-B37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2012.04.006","article-title":"Pathophysiology of osteoporosis: new mechanistic insights","volume":"41","author":"Armas","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"2024041923080914200_dgad711-B38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrrheum.2012.93","article-title":"Recognizing and treating secondary osteoporosis","volume":"8","author":"Walker-Bone","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"8 Suppl","key":"2024041923080914200_dgad711-B39","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"issue":"2","key":"2024041923080914200_dgad711-B40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/1078-0432.CCR-10-2507","article-title":"Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL\/RANK\/OPG pathway in tumorigenesis and metastasis","volume":"18","author":"Dougall","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024041923080914200_dgad711-B41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-018-1001-2","article-title":"RANKL\/RANK\/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives","volume":"38","author":"Infante","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2024041923080914200_dgad711-B42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: the importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2024041923080914200_dgad711-B43","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"issue":"11","key":"2024041923080914200_dgad711-B44","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2009.04.022","article-title":"Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?","volume":"45","author":"Coleman","year":"2009","journal-title":"Eur J Cancer"},{"issue":"35","key":"2024041923080914200_dgad711-B45","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024041923080914200_dgad711-B46","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2024041923080914200_dgad711-B47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2024041923080914200_dgad711-B48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000645","article-title":"Current concepts in the treatment of giant cell tumour of bone","volume":"32","author":"van der Heijden","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"2024041923080914200_dgad711-B49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/ans.17520","article-title":"Metastatic giant cell tumour of bone: a narrative review of management options and approaches","volume":"92","author":"Xu","year":"2022","journal-title":"ANZ J Surg"},{"issue":"Suppl 2","key":"2024041923080914200_dgad711-B50","first-page":"ii11","article-title":"Pathogenesis of bone and cartilage destruction in rheumatoid arthritis","volume":"42","author":"Goldring","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2024041923080914200_dgad711-B51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.bor.0000231912.24740.a5","article-title":"Osteoclasts, rheumatoid arthritis, and osteoimmunology","volume":"18","author":"Sato","year":"2006","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"2024041923080914200_dgad711-B52","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","article-title":"Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment","volume":"8","author":"Schett","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2024041923080914200_dgad711-B53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrd3669","article-title":"Inflammatory bone loss: pathogenesis and therapeutic intervention","volume":"11","author":"Redlich","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2024041923080914200_dgad711-B54","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bone.2010.12.023","article-title":"RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II","volume":"48","author":"Hemingway","year":"2011","journal-title":"Bone"},{"issue":"2","key":"2024041923080914200_dgad711-B55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.191.2.275","article-title":"Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction","volume":"191","author":"Kobayashi","year":"2000","journal-title":"J Exp Med"},{"issue":"5","key":"2024041923080914200_dgad711-B56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1084\/jem.20050978","article-title":"Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis","volume":"202","author":"Kim","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"2024041923080914200_dgad711-B57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.38218","article-title":"Combination of tumor necrosis factor alpha and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo","volume":"66","author":"Yokota","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2024041923080914200_dgad711-B58","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/art.39837","article-title":"RANK-Independent Osteoclast formation and bone erosion in inflammatory arthritis","volume":"68","author":"O'Brien","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"14","key":"2024041923080914200_dgad711-B59","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s00018-018-2817-9","article-title":"Mechanisms involved in normal and pathological osteoclastogenesis","volume":"75","author":"Park-Min","year":"2018","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"2024041923080914200_dgad711-B60","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2024041923080914200_dgad711-B61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40634-019-0211-7","article-title":"Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates","volume":"6","author":"Kaneko","year":"2019","journal-title":"J Exp Orthop"},{"issue":"6","key":"2024041923080914200_dgad711-B62","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/annrheumdis-2014-207137","article-title":"RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation","volume":"75","author":"Danks","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024041923080914200_dgad711-B63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev-immunol-042718-041728","article-title":"The myeloid cell compartment-cell by cell","volume":"37","author":"Bassler","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2024041923080914200_dgad711-B64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.11005\/jbm.2023.30.2.127","article-title":"Origin of osteoclasts\u2014osteoclast precursor cells","volume":"30","author":"Jefferson Tsai","year":"2023","journal-title":"J Bone Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad711\/55367370\/dgad711.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/5\/e1373\/57285959\/dgad711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/5\/e1373\/57285959\/dgad711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T23:10:18Z","timestamp":1713568218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/5\/e1373\/7462181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,12,7]]},"published-print":{"date-parts":[[2024,4,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad711","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2023,12,7]]}}}